-
May 17, 2013
Betmiga gets final draft yes from the Institute as Astellas looks to replace its ageing OAB drug Vesicare
Full story
-
May 14, 2013
SMC green light for Shire's ADHD drug Elvanse, Novartis eye drug Lucentis and Astellas Betmiga for overactive bladder, but it's a no for Pfizer personalised NSCLC drug Xalkori.
Full story
-
May 03, 2013
US biotech Aveo Oncology saw its shares in a downward spiral yesterday after advisors to the FDA rejected its experimental kidney cancer drug tivozanib.
Full story
-
April 27, 2013
The latest set of opinions from advisors to the European Medicines Agency sees five new medicines and two generics recommended for approval
Full story
-
April 09, 2013
Five Japanese pharmaceutical companies have joined a public-private partnership with the government of Japan and the Bill & Melinda Gates Foundation to advance research and development of new medicines, vaccines and diagnostics targeting infectious diseases in the developing world.
Full story
-
April 05, 2013
Astellas Pharma has linked up with Ambrx of the USA to discover and develop antibody drug conjugates
Full story
-
March 12, 2013
Eyebrows have been raised after Astellas Pharma decided to end its collaboration with Ambit Biosciences Corp to develop the latter's acute myeloid leukaemia treatment quizartinib
Full story
-
December 18, 2012
Astellas' Dificlir is now routinely available for National Health Service patients in Wales after advisors recommended the drug's use for treating the hospital superbug C. difficile.
Full story
-
December 09, 2012
The promise shown by Ambit Biosciences' quizartinib, which is partnered with Astellas, as a treatment for acute myeloid leukaemia, has caused a stir at ASH
Full story
-
December 05, 2012
Japanese firm expands early-stage clinical trial facility in Bucks
Full story